Mezzion Pharma메지온
140410 · KOSDAQ · ₩140410 · 메지온
- Market cap
- ₩1.6T
- Enterprise value
- ₩1.6T
- P/E
- —
- P/B
- 41.6×
- Dividend yield
- 0.0%
- ROE
- −70.2%
- Net margin
- −325.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.8% from the high
₩45,850Today: ₩51,900 – ₩55,100₩179,900
Returns
- 1W−12.0%
- 1M−33.2%
- 3M+0.8%
- 6M−45.2%
- YTD−41.6%
- 1Y−13.6%
- Volume today
- 161,744
- 1.6× the 20-day average
- Traded today
- ₩8.6B
- Listed shares
- 30,876,230
- EPS (12 months)
- −₩887
- Earnings yield −1.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 50 of 100 (50 is a normal day for this stock).
- MomentumWeak-36% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 28: buy ₩2.8B at the close (42.3% of 20-day average trading value)
On its 28 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 24.0% of trading value and pointed the same way 18 of 28 times.
- 2× KODEX KOSDAQ150 Leverage ₩2.5B
- -1× KODEX KOSDAQ150 Futures Inverse ₩141M
- 2× TIGER KOSDAQ150 Leverage ₩128M
- 2× RISE KOSDAQ150 Futures Leverage ₩24M
- -1× TIGER KOSDAQ150 Futures Inverse ₩4.6M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.6%
- KODEX KOSDAQ150 Leverage2×0.6%
- TIGER KOSDAQ1500.6%
- RISE KOSDAQ1500.6%
- TIGER KOSDAQ150 Leverage2×0.6%
- ACE KOSDAQ 1500.6%
- KIWOOM KOSDAQ1500.6%
- SOL KOSDAQ1500.6%
Estimated from the funds' index or underlying stock.
Mezzion Pharma stock overview
Mezzion Pharma (메지온, KRX: 140410) is listed on KOSDAQ, in the Biotech & Pharma sector. Mezzion is a Korean drug development company founded in 2002 that focuses on developing new drugs for global markets. Its shares closed at ₩52,600 on Oct 28, 2026, down 2.41% on the day, giving it a market value of ₩1.6T.
Key facts
- Market cap
- ₩1.6T
- Sector
- Biotech & Pharma
- Latest price change
- −2.41%
- As of
- Oct 28, 2026
- Main business
- Mezzion is a Korean drug development company founded in 2002 that focuses on developing new drugs for global markets.
Quick answers about Mezzion Pharma
- What does Mezzion Pharma do?
- Mezzion is a Korean drug development company founded in 2002 that focuses on developing new drugs for global markets. Its lead candidate is udenafil, which it is developing for Fontan circulation patients with single ventricle heart disease, a rare condition, and for autosomal dominant polycystic kidney disease. The company licenses its drug candidates to partners, and its current revenue comes from a domestic animal feed business.
- What is the market cap of Mezzion Pharma?
- The market capitalisation of Mezzion Pharma was ₩1.6T at the close on Oct 28, 2026.
- Who are the largest shareholders of Mezzion Pharma?
- According to the latest official filings, the largest reported holders are KayneHoldingsL.P. (6.52%, as of Oct 8, 2026); Park Dong-hyun (6.02%, as of Oct 29, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.09%, as of Jul 31, 2026).
- When is the next earnings report from Mezzion Pharma?
- Korean companies rarely announce results dates in advance. Based on when Mezzion Pharma filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Mezzion Pharma?
- Yes. The National Pension Service held 0.50% of Mezzion Pharma shares as of Dec 31, 2025.
Company profile
Mezzion is a Korean drug development company founded in 2002 that focuses on developing new drugs for global markets. Its lead candidate is udenafil, which it is developing for Fontan circulation patients with single ventricle heart disease, a rare condition, and for autosomal dominant polycystic kidney disease. The company licenses its drug candidates to partners, and its current revenue comes from a domestic animal feed business.
Written by AI from the company's latest annual report.
- Korean name
- 메지온
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 박동현
- Founded
- Sep 2002
- Listed
- Jan 2012
- Listed shares
- 30,876,230
- Fiscal year ends
- Month 12
- Website
- -
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Insider shareholding reportOct 29, 2026
- Insider shareholding reportOct 20, 2026
- 5%+ holding reportOct 8, 2026
- 5%+ holding reportOct 2, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Mezzion Pharma / 메지온 / 140410 / KRX:140410
Source: KRX statistical information